• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hematological Tumor - Pipeline Review, H2 2012 Product Image

Hematological Tumor - Pipeline Review, H2 2012

  • Published: December 2012
  • 232 pages
  • Global Markets Direct

Hematological Tumor – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Hematological Tumor - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hematological Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hematological Tumor. Hematological Tumor - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hematological Tumor.
- A review of the Hematological Tumor products under development by companies and universities/research READ MORE >

2
List of Tables 5
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Hematological Tumor Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Hematological Tumor 11
Hematological Tumor Therapeutics under Development by Companies 13
Hematological Tumor Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
Hematological Tumor Therapeutics – Products under Development by Companies 23
Hematological Tumor Therapeutics – Products under Investigation by Universities/Institutes 28
Companies Involved in Hematological Tumor Therapeutics Development 29
Genzyme Corporation 29
F. Hoffmann-La Roche Ltd. 30
Sanofi-Aventis 31
AstraZeneca PLC 32
Eli Lilly and Company 33
MedImmune LLC 34
Gamida Cell Ltd. 35
Infinity Pharmaceuticals, Inc. 36
Millennium Pharmaceuticals, Inc. 37
Novartis AG 38
Ono Pharmaceutical Co., Ltd. 39
Cyclacel Pharmaceuticals Inc. 40
Onyx Pharmaceuticals, Inc. 41
Merck KGaA 42
Access Pharmaceuticals, Inc. 43
4SC AG 44
EntreMed, Inc. 45
Idera Pharmaceuticals, Inc. 46
Marshall Edwards, Inc. 47
Curis, Inc. 48
Jazz Pharmaceuticals, Inc. 49
Case Comprehensive Cancer Center 50
Pharmacyclics, Inc. 51
Threshold Pharmaceuticals, Inc. 52
Synta Pharmaceuticals Corp. 53
Oryzon 54
Nerviano Medical Sciences S.r.l. 55
Aegera Therapeutics Inc. 56
Altor BioScience Corporation 57
Arno Therapeutics, Inc. 58
ACT Biotech, Inc. 59
Stemline Therapeutics, Inc. 60
AndroScience Corporation 61
Onconova Therapeutics, Inc 62
Concert Pharmaceuticals, Inc. 63
NOXXON Pharma AG 64
Fate Therapeutics, Inc. 65
Esperance Pharmaceuticals, Inc. 66
Y's Therapeutics Co., Ltd. 67
KaloBios Pharmaceuticals, Inc. 68
Aprea AB. 69
Biokine Therapeutics Ltd. 70
Cylene Pharmaceuticals, Inc. 71
TRACON Pharmaceuticals, Inc. 72
TheraCarb Inc. 73
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. 74
Dynamix Pharmaceuticals Ltd. 75
Jiangsu Kanion Pharmaceutical Co., Ltd. 76
XBiotech USA, Inc. 77
IkerChem S.L. 78
Hematological Tumor – Therapeutics Assessment 79
Assessment by Monotherapy Products 79
Assessment by Combination Products 80
Assessment by Route of Administration 81
Assessment by Molecule Type 83
Drug Profiles 85
ixazomib citrate - Drug Profile 85
alisertib - Drug Profile 87
Thiarabine - Drug Profile 89
abexinostat - Drug Profile 91
ENMD-2076 - Drug Profile 93
panobinostat - Drug Profile 95
SAR-650984 - Drug Profile 98
pimasertib - Drug Profile 100
oprozomib - Drug Profile 102
lucatumumab - Drug Profile 104
SB-939 - Drug Profile 106
ganetespib - Drug Profile 108
TH-302 - Drug Profile 111
SL-201 - Drug Profile 113
rigosertib - Drug Profile 114
NOX-A-12 - Drug Profile 117
MLN-0128 - Drug Profile 119
KB-004 - Drug Profile 120
IMO-4200 - Drug Profile 122
YS-110 - Drug Profile 124
DNMT Inhibitors - Drug Profile 125
JMJ Inhibitors - Drug Profile 126
IKH-02 - Drug Profile 127
ACTB-1010 - Drug Profile 128
MEDI-551 - Drug Profile 129
AR-12 - Drug Profile 131
APR-246 - Drug Profile 132
fludarabine phosphate - Drug Profile 133
fenretinide - Drug Profile 134
NMS-1116354 - Drug Profile 136
clofarabine - Drug Profile 137
nivolumab - Drug Profile 138
fostamatinib disodium - Drug Profile 140
asparaginase erwinia chrysanthemi - Drug Profile 143
OPB-51602 - Drug Profile 145
ALT-803 - Drug Profile 146
IPI-145 - Drug Profile 148
CU-201 - Drug Profile 150
EP-400 Series - Drug Profile 151
CYC-065 - Drug Profile 152
Cancer Program - Drug Profile 153
CA-18C3 - Drug Profile 154
gandotinib - Drug Profile 155
Proteasome Inhibitors - Drug Profile 157
NK Cell Product - Drug Profile 158
TRC102 + Fludara - Drug Profile 160
C-21359 - Drug Profile 161
DNX-4000 - Drug Profile 162
LGH-447 - Drug Profile 163
CX-7168 - Drug Profile 164
CX-6880 - Drug Profile 165
ProHema - Drug Profile 166
CX-7298 - Drug Profile 168
CX-7197 - Drug Profile 169
CX-7238 - Drug Profile 170
CX-7372 - Drug Profile 171
CX-7381 - Drug Profile 172
RG-7388 - Drug Profile 173
LY278544 - Drug Profile 174
ASC-ST.X1 - Drug Profile 176
BKT-140 Oral - Drug Profile 177
SEL-120 Program - Drug Profile 178
Vif-derived Peptide - Drug Profile 179
KPT-330 - Drug Profile 180
Naive T Cell Depleted Donor Lymphocyte Infusion - Drug Profile 181
Fludarabine Phosphate + Methoxyamine - Drug Profile 182
NT-113 - Drug Profile 183
NT-125 - Drug Profile 184
Hedgehog Inhibitor - Drug Profile 185
Pim Inhibitor Program - Drug Profile 186
Vaccine For Cancer - Drug Profile 187
BTK Kinase Inhibitors - Drug Profile 188
WNT Inhibitor - Drug Profile 189
Histone Deacetylase 2 Selective Inhibitor - Drug Profile 190
Hematological Tumor Therapeutics – Drug Profile Updates 191
Hematological Tumor Therapeutics – Discontinued Products 219
Hematological Tumor Therapeutics - Dormant Products 220
Hematological Tumor – Product Development Milestones 221
Featured News & Press Releases 221
Appendix 226
Methodology 226
Coverage 226
Secondary Research 226
Primary Research 226
Expert Panel Validation 226
Contact Us 227
Disclaimer 227

List of Tables
Number of Products Under Development for Hematological Tumor, H2 2012 16
Products under Development for Hematological Tumor – Comparative Analysis, H2 2012 17
Number of Products under Development by Companies, H2 2012 19
Number of Products under Development by Companies, H2 2012 (Contd..1) 20
Number of Products under Development by Companies, H2 2012 (Contd..2) 21
Number of Products under Development by Companies, H2 2012 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H2 2012 23
Comparative Analysis by Late Stage Development, H2 2012 24
Comparative Analysis by Mid Clinical Stage Development, H2 2012 25
Comparative Analysis by Early Clinical Stage Development, H2 2012 26
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 27
Products under Development by Companies, H2 2012 28
Products under Development by Companies, H2 2012 (Contd..1) 29
Products under Development by Companies, H2 2012 (Contd..2) 30
Products under Development by Companies, H2 2012 (Contd..3) 31
Products under Development by Companies, H2 2012 (Contd..4) 32
Products under Investigation by Universities/Institutes, H2 2012 33
Genzyme Corporation, H2 2012 34
F. Hoffmann-La Roche Ltd., H2 2012 35
Sanofi-Aventis, H2 2012 36
AstraZeneca PLC, H2 2012 37
Eli Lilly and Company, H2 2012 38
MedImmune LLC, H2 2012 39
Gamida Cell Ltd., H2 2012 40
Infinity Pharmaceuticals, Inc., H2 2012 41
Millennium Pharmaceuticals, Inc., H2 2012 42
Novartis AG, H2 2012 43
Ono Pharmaceutical Co., Ltd., H2 2012 44
Cyclacel Pharmaceuticals Inc., H2 2012 45
Onyx Pharmaceuticals, Inc., H2 2012 46
Merck KGaA, H2 2012 47
Access Pharmaceuticals, Inc., H2 2012 48
4SC AG, H2 2012 49
EntreMed, Inc., H2 2012 50
Idera Pharmaceuticals, Inc., H2 2012 51
Marshall Edwards, Inc., H2 2012 52
Curis, Inc., H2 2012 53
Jazz Pharmaceuticals, Inc., H2 2012 54
Case Comprehensive Cancer Center, H2 2012 55
Pharmacyclics, Inc., H2 2012 56
Threshold Pharmaceuticals, Inc., H2 2012 57
Synta Pharmaceuticals Corp., H2 2012 58
Oryzon, H2 2012 59
Nerviano Medical Sciences S.r.l., H2 2012 60
Aegera Therapeutics Inc., H2 2012 61
Altor BioScience Corporation, H2 2012 62
Arno Therapeutics, Inc., H2 2012 63
ACT Biotech, Inc., H2 2012 64
Stemline Therapeutics, Inc., H2 2012 65
AndroScience Corporation, H2 2012 66
Onconova Therapeutics, Inc, H2 2012 67
Concert Pharmaceuticals, Inc., H2 2012 68
NOXXON Pharma AG, H2 2012 69
Fate Therapeutics, Inc., H2 2012 70
Esperance Pharmaceuticals, Inc., H2 2012 71
Y's Therapeutics Co., Ltd., H2 2012 72
KaloBios Pharmaceuticals, Inc., H2 2012 73
Aprea AB., H2 2012 74
Biokine Therapeutics Ltd., H2 2012 75
Cylene Pharmaceuticals, Inc., H2 2012 76
TRACON Pharmaceuticals, Inc., H2 2012 77
TheraCarb Inc., H2 2012 78
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., H2 2012 79
Dynamix Pharmaceuticals Ltd., H2 2012 80
Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2012 81
XBiotech USA, Inc., H2 2012 82
IkerChem S.L., H2 2012 83
Assessment by Monotherapy Products, H2 2012 84
Assessment by Combination Products, H2 2012 85
Assessment by Stage and Route of Administration, H2 2012 87
Assessment by Stage and Molecule Type, H2 2012 89
Hematological Tumor Therapeutics – Drug Profile Updates 196
Hematological Tumor Therapeutics – Discontinued Products 224
Hematological Tumor Therapeutics – Dormant Products 225

List of Figures
Number of Products under Development for Hematological Tumor, H2 2012 16
Products under Development for Hematological Tumor – Comparative Analysis, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 23
Late Stage Products, H2 2012 24
Mid Clinical Stage Products, H2 2012 25
Early Clinical Stage Products, H2 2012 26
Discovery and Pre-Clinical Stage Products, H2 2012 27
Assessment by Monotherapy Products, H2 2012 84
Assessment by Combination Products, H2 2012 85
Assessment by Route of Administration, H2 2012 86
Assessment by Stage and Route of Administration, H2 2012 87
Assessment by Molecule Type, H2 2012 88
Assessment by Stage and Molecule Type, H2 2012 89

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos